SIBN trades 38.5% below Wall Street's consensus target of $24.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SIBN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, SI-BONE, Inc. (SIBN) has a Wall Street consensus price target of $24.00, based on estimates from 9 covering analysts. With the stock currently trading at $17.33, this represents a potential upside of +38.5%. The company has a market capitalization of $769M.
Analyst price targets range from a low of $24.00 to a high of $24.00, representing a 0% spread in expectations. The median target of $24.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SIBN trades at a trailing P/E of -39.4x. Analysts expect EPS to grow -14.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
XTNTXtant Medical Holdings, Inc. | $59M | $0.42 | — | — | — | — | — |
ATECAlphatec Holdings, Inc. | $1.4B | $9.30 | $18.00 | +93.5% | Buy | 29.1x | 18 |
NVAXNovavax, Inc. | $1.5B | $8.88 | $18.00 | +102.7% | Buy | — | 23 |
GMEDGlobus Medical, Inc. | $11.6B | $86.25 | $109.50 | +27.0% | Buy | 18.2x | 36 |
OSISOSI Systems, Inc. | $3.6B | $218.29 | $310.00 | +42.0% | Buy | 20.9x | 18 |
OFIXOrthofix Medical Inc. | $395M | $9.78 | $15.60 | +59.5% | Hold | — | 17 |
IARTIntegra LifeSciences Holdings Corporation | $1.5B | $18.76 | $18.50 | -1.4% | Buy | 7.7x | 26 |
MMSIMerit Medical Systems, Inc. | $4.3B | $71.73 | $94.20 | +31.3% | Buy | 17.6x | 14 |
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
ZBHZimmer Biomet Holdings, Inc. | $18.2B | $93.10 | $96.33 | +3.5% | Hold | 11.0x | 42 |
Quick answers to the most common questions about buying SIBN stock.
The consensus Wall Street price target for SIBN is $24, representing 38.5% upside from the current price of $17.33. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SIBN has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $24 implies 38.5% upside from current levels.
SIBN's current price is $17.33 with a consensus target of $24 (38.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $24 for SIBN, while the most conservative target is $24. The consensus of $24 represents the median expectation. These targets typically reflect 12-month expectations.
SIBN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SIBN stock forecast based on 9 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $24 (bear case) to $24 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SIBN, with a "Buy" consensus rating and $24 price target (38.5% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SIBN analyst price targets range from $24 to $24, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.